Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

SIMPLE SUMMARY: Second-line treatment strategy after the first-line CDK4/6 inhibitor with aromatase inhibitor is considered by the behavior of hormone receptor positive human epidermal growth factor receptor-2 negative (HR+HER2−) metastatic breast cancer (MBC). Progression free survival 2 was one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Shin, Junghoon, Ahn, Jin Seok, Park, Yeon Hee, Im, Young-Hyuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341332/
https://www.ncbi.nlm.nih.gov/pubmed/37444541
http://dx.doi.org/10.3390/cancers15133431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341332/
https://www.ncbi.nlm.nih.gov/pubmed/37444541
http://dx.doi.org/10.3390/cancers15133431

Ejemplares similares